Global enrollment was completed in December with a total of patients. 환자들은 무작위로 두 가지 용량의 마키텐탄 1mg과 2mg을 1일 1회 투여하거나 위약을 투여하도록 배정되었습니다. Patients were allowed to receive PAH background therapy throughout the study, either PDE inhibitors or oralinhaled prostanoids.